Cargando…

Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study

SIMPLE SUMMARY: Patients suffering from glioblastoma receive treatment according to the Stupp protocol. After chemoradiotherapy, the glioblastoma either continue to develop, or treatment-related vascular damage comes into play, both causing new, seemingly identical contrast-enhancing lesions in foll...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Elshout, Rik, Herings, Siem D. A., Mannil, Manoj, Gijtenbeek, Anja M. M., ter Laan, Mark, Smeenk, Robert J., Meijer, Frederick J. A., Scheenen, Tom W. J., Henssen, Dylan J. H. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605800/
https://www.ncbi.nlm.nih.gov/pubmed/37894355
http://dx.doi.org/10.3390/cancers15204990
_version_ 1785127165313941504
author van den Elshout, Rik
Herings, Siem D. A.
Mannil, Manoj
Gijtenbeek, Anja M. M.
ter Laan, Mark
Smeenk, Robert J.
Meijer, Frederick J. A.
Scheenen, Tom W. J.
Henssen, Dylan J. H. A.
author_facet van den Elshout, Rik
Herings, Siem D. A.
Mannil, Manoj
Gijtenbeek, Anja M. M.
ter Laan, Mark
Smeenk, Robert J.
Meijer, Frederick J. A.
Scheenen, Tom W. J.
Henssen, Dylan J. H. A.
author_sort van den Elshout, Rik
collection PubMed
description SIMPLE SUMMARY: Patients suffering from glioblastoma receive treatment according to the Stupp protocol. After chemoradiotherapy, the glioblastoma either continue to develop, or treatment-related vascular damage comes into play, both causing new, seemingly identical contrast-enhancing lesions in follow-up MRI, where clinicians and radiologists alike can only differentiate between tumor progression (TP) and treatment-related abnormalities (TRA) by seeing the temporal evolution of the lesion and the patients clinical status. We investigate the use of diffusion MRI and the quantitative apparent diffusion coefficient (ADC) in a retrospective patient cohort and we sought to validate a previously reported ADC cutoff value for its distinctive properties between TP and TRA. In the end, ADC values were shown not to be highly discriminative and, compared to the mean ADC values between TP and TRA previously reported in the literature, are more overlapping than expected. ABSTRACT: Distinguishing treatment-related abnormalities (TRA) from tumor progression (TP) in glioblastoma patients is a diagnostic imaging challenge due to the identical morphology of conventional MR imaging sequences. Diffusion-weighted imaging (DWI) and its derived images of the apparent diffusion coefficient (ADC) have been suggested as diagnostic tools for this problem. The aim of this study is to determine the diagnostic accuracy of different cut-off values of the ADC to differentiate between TP and TRA. In total, 76 post-treatment glioblastoma patients with new contrast-enhancing lesions were selected. Lesions were segmented using a T1-weighted, contrast-enhanced scan. The mean ADC values of the segmentations were compared between TRA and TP groups. Diagnostic accuracy was compared by use of the area under the curve (AUC) and the derived sensitivity and specificity values from cutoff points. Although ADC values in TP (mean = 1.32 × 10(−3) mm(2)/s; SD = 0.31 × 10(−3) mm(2)/s) were significantly different compared to TRA (mean = 1.53 × 10(−3) mm(2)/s; SD = 0.28 × 10(−3) mm(2)/s) (p = 0.003), considerable overlap in their distributions exists. The AUC of ADC values to distinguish TP from TRA was 0.71, with a sensitivity and specificity of 65% and 70%, respectively, at an ADC value of 1.47 × 10(−3) mm(2)/s. These findings therefore indicate that ADC maps should not be used in discerning between TP and TRA at a certain timepoint without information on temporal evolution.
format Online
Article
Text
id pubmed-10605800
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106058002023-10-28 Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study van den Elshout, Rik Herings, Siem D. A. Mannil, Manoj Gijtenbeek, Anja M. M. ter Laan, Mark Smeenk, Robert J. Meijer, Frederick J. A. Scheenen, Tom W. J. Henssen, Dylan J. H. A. Cancers (Basel) Article SIMPLE SUMMARY: Patients suffering from glioblastoma receive treatment according to the Stupp protocol. After chemoradiotherapy, the glioblastoma either continue to develop, or treatment-related vascular damage comes into play, both causing new, seemingly identical contrast-enhancing lesions in follow-up MRI, where clinicians and radiologists alike can only differentiate between tumor progression (TP) and treatment-related abnormalities (TRA) by seeing the temporal evolution of the lesion and the patients clinical status. We investigate the use of diffusion MRI and the quantitative apparent diffusion coefficient (ADC) in a retrospective patient cohort and we sought to validate a previously reported ADC cutoff value for its distinctive properties between TP and TRA. In the end, ADC values were shown not to be highly discriminative and, compared to the mean ADC values between TP and TRA previously reported in the literature, are more overlapping than expected. ABSTRACT: Distinguishing treatment-related abnormalities (TRA) from tumor progression (TP) in glioblastoma patients is a diagnostic imaging challenge due to the identical morphology of conventional MR imaging sequences. Diffusion-weighted imaging (DWI) and its derived images of the apparent diffusion coefficient (ADC) have been suggested as diagnostic tools for this problem. The aim of this study is to determine the diagnostic accuracy of different cut-off values of the ADC to differentiate between TP and TRA. In total, 76 post-treatment glioblastoma patients with new contrast-enhancing lesions were selected. Lesions were segmented using a T1-weighted, contrast-enhanced scan. The mean ADC values of the segmentations were compared between TRA and TP groups. Diagnostic accuracy was compared by use of the area under the curve (AUC) and the derived sensitivity and specificity values from cutoff points. Although ADC values in TP (mean = 1.32 × 10(−3) mm(2)/s; SD = 0.31 × 10(−3) mm(2)/s) were significantly different compared to TRA (mean = 1.53 × 10(−3) mm(2)/s; SD = 0.28 × 10(−3) mm(2)/s) (p = 0.003), considerable overlap in their distributions exists. The AUC of ADC values to distinguish TP from TRA was 0.71, with a sensitivity and specificity of 65% and 70%, respectively, at an ADC value of 1.47 × 10(−3) mm(2)/s. These findings therefore indicate that ADC maps should not be used in discerning between TP and TRA at a certain timepoint without information on temporal evolution. MDPI 2023-10-14 /pmc/articles/PMC10605800/ /pubmed/37894355 http://dx.doi.org/10.3390/cancers15204990 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
van den Elshout, Rik
Herings, Siem D. A.
Mannil, Manoj
Gijtenbeek, Anja M. M.
ter Laan, Mark
Smeenk, Robert J.
Meijer, Frederick J. A.
Scheenen, Tom W. J.
Henssen, Dylan J. H. A.
Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
title Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
title_full Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
title_fullStr Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
title_full_unstemmed Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
title_short Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
title_sort apparent diffusion coefficient metrics to differentiate between treatment-related abnormalities and tumor progression in post-treatment glioblastoma patients: a retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605800/
https://www.ncbi.nlm.nih.gov/pubmed/37894355
http://dx.doi.org/10.3390/cancers15204990
work_keys_str_mv AT vandenelshoutrik apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT heringssiemda apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT mannilmanoj apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT gijtenbeekanjamm apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT terlaanmark apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT smeenkrobertj apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT meijerfrederickja apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT scheenentomwj apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy
AT henssendylanjha apparentdiffusioncoefficientmetricstodifferentiatebetweentreatmentrelatedabnormalitiesandtumorprogressioninposttreatmentglioblastomapatientsaretrospectivestudy